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Fenugreek is known since ancient times as a traditional herbal medicine of its multiple beneficial effects. Fenugreek’s most studied
and employed effect is its hypoglycemic property, but it can also be useful for the treatment of certain thyroid disorders or for the
treatment of anorexia. The regulation of glucose homeostasis is a complex mechanism, dependent on the interaction of different
types of hormones and neurotransmitters or other compounds. For the study of how diosgenin and fenugreek seeds modify
insulin sensitivity, we used a rat insulin resistance model induced by high-fat diet. Diosgenin in three different doses (1mg/bwkg,
10mg/bwkg, and 50mg/bwkg, respectively) and fenugreek seed (0.2 g/bwkg)were administered orally for 6weeks. Insulin sensitivity
was determined by hyperinsulinemic euglycemic glucose clampmethod. Our research group found that although glucose infusion
rate was not significantly modified in either group, the increased insulin sensitivity index and high metabolic clearance rate of
insulin found in the 1 mg/kg diosgenin and the fenugreek seed treated group suggested an improved peripheral insulin sensitivity.
Results from the 10 mg/kg diosgenin group, however, suggest a marked insulin resistance. Fenugreek seed therapy results on
the investigated anabolic hormones support the theory that, besides insulin and gastrointestinal peptides, the hypothalamic-
hypopituitary axis regulated hormones synchronized action with IGF-1 also play an important role in the maintaining of normal
glucose levels. Both diosgenin and fenugreek seeds are capable of interacting with substrates of the above-mentioned regulatory
mechanisms, inducing serious hormonal disorders. Moreover, fenugreek seeds showed the ability to reduce the thyroid hormone
levels at the periphery and to modify the T4/T3 ratio. It means that in healthy people this effect could be considered a severe side
effect; however, in hypothyroidism this effect represents a possibility of alternative natural therapy.
1. Introduction
Fenugreek (Trigonella foenum-graecum) appears to be rich in
phytonutrients with multiple pharmacological effects [1–4].
Extracts have been made using fenugreek vegetative organs
and/or seeds, andmultiple in vivo and in vitro studies revealed
analgesic [5, 6], hepatoprotective [7, 8], and hypolipidemic
[9–14] effects. It was suggested that the hypolipidemic effects
could be put on the expense of saponins that transformed
into sapogenins in the gastrointestinal tract would trigger
the reduction of serum cholesterol levels [15, 16]. Among
saponins, the diosgenin was found to induce changes in the
lipid profile of different tissues or organs, such as plasma,
liver, heart, or brain in a diabetic rat model [17], indicating
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that these modifications might be correlated with a hypo-
glycemic effect. In another study, it was demonstrated that
both fenugreek and diosgenin treatment prevented high-fat,
high-sugar diet-induced endothelial dysfunction, and redox
changes [18]. Besides diosgenin, the 4-hydroxyisoleucine (4-
HIL), a fairly rare amino acid found in fenugreek, was shown
to increase insulin secretion upon glucose stimulation [19,
20]. Moreover, 4-HIL could reduce insulin resistance (IR) in
muscle and/or liver by stimulating phosphoinositide 3 (PI3)
kinase activity [21]. Interestingly, increased insulin receptor
[22], adiponectin, and PPAR𝛾 [23] expression were also
associated with the IR reducing effects of fenugreek. These
results, together with the fenugreek seed administration
induced improvement of hepatic steatosis, strongly plead for
a cause-and-effect type of relationship between liver specific
IR and steatosis [23]. It is also demonstrated that the health
promoting effect of fenugreek is mostly due to its antioxidant
capacity [24]. Among phytonutrients, the polyphenols from
fenugreek seeds were shown to exert antioxidant properties
by inhibiting lipid peroxidation [8]. A fenugreek seed and/or
seed extracts were found to increase glucose uptake; reduced
glycosylated haemoglobin levels together with proinflamma-
tory cytokines and pancreatic enzymes; in dose-dependent
manner restored the glycogen levels in muscle and liver;
inhibited lipid peroxidation; and reinstated some antioxi-
dant enzymes-glutathione (GSH) and superoxide dismutase
(SOD) activities in the liver and pancreas [25]. It has also
been suggested that, in the case of fenugreek, the antioxidant
potential complements the hypolipidemic, hypoglycemic,
and anti-inflammatory effects [26]. Accordingly, diabetic rats
treated with fenugreek showed reduced serum glucose levels,
and the activities of antioxidant defence enzymes increased
due to the expression of the mentioned genes in the liver
or/and brain [27]. Another study concluded that fenugreek
seed extract could efficiently suppress testicular oxidative
stress in combination with apoptosis and inflammation [28].
Interestingly, a comparative study showed substantial differ-
ences between the antioxidant activity of fenugreek leaf and
seed extracts with respect to the DNA damage protective
activities [29]. Another study was indicating a functional link
between the antioxidant and anticancer effects of fenugreek
[30]. Nevertheless, the anticancer effect of fenugreek has been
thoroughly assessed [31–33], and selective cytotoxicity has
been observed in case of various cancer cell lines. Thus, for
example, in the case of breast cancer, T cell lymphoma, B
cell lymphoma, and thyroid papillary carcinoma cell lines,
significant cytotoxic effects were observed while no signifi-
cant cytotoxicity was evident for normal human cells. [28].
Furthermore, Vı´gh et al. were able to correlate the chemical
composition of fenugreek seed extracts with reduced viability
of the T-47D and ZR-75-1 breast cancer cell lines [34]. More-
over, they could also show that an aqueous fenugreek seed
extract could affect the viability of cancerous cells in a dose-
dependent antagonistic fashion. However, only diosgenin
from fenugreek was proven to efficiently reduce cancer cell
viability, while inducing apoptosis [35]. More specifically, it
was ascertained that diosgenin inhibited telomerase activity
by downregulating the hTERT gene expression could reverse
multidrug resistance in cancer cells by sensitizing them to
standard chemotherapy, activating p53 gene and the STAT3
signalling pathway [36–38]. In addition to fenugreek benefi-
cial properties, some toxic effectswere also reported related to
embryonic development, spermatogenesis, allergic reactions,
neurotoxicity, and altered levels of thyroid hormones or
inhibition of hematopoietic regulatory elements [39].
Taken together, plethora of research has been conducted
to analyze independently the fenugreek composition and the
generated biological effects, yet studies to relate composition
to function are available in limited numbers, mostly due to
the limitation of research models and methodology. Among
the constituents of fenugreek, diosgenin stands at the fore-
front of current research, and results are indicating multiple
biological effects depending on the characteristics of assessed
models. Our research reported in current paper describes
a comparative dose-dependent study based on fenugreek
and diosgenin in conjunction with an improved peripheral
insulin sensitivity and the interference with hypothalamic-
hypopituitary axis regulated hormones. To the best of
our knowledge there is no published evidence suggesting
the interdependence between the possible concentration-
dependent toxic effects of fenugreek treatment and the most
important anabolic hormones, such as the growth hormone,
IGF-1, T3, and T4. Our results further demonstrate the
importance of careful dose-dependent assessment of fenu-
greek specific pharmacological effects.
2. Materials and Methods
2.1. Analytical Examination of Fenugreek Seeds
2.1.1. Preparation of Extract. The seeds of fenugreek were
obtained from an authorized local distributor. Powdered
fenugreek seeds were extracted with water: ethanol mixture
(1:1) for 72 h at 70∘C using Soxhlet apparatus.This extract was
then concentrated to dryness by removing the solvent in the
rotary evaporator under reduced pressure.
2.1.2. Preparation of Sample for Analysis. One gram of thor-
oughlymilled fenugreek seeds was accurately weighed. To the
fine powder obtained, 80 mL of 3 M hydrochloric acid was
added, and then it was kept on reflux for 1 h on water bath
at 100∘C. Mixture was allowed to cool at room temperature
and was diluted further up to the mark with water. Diethyl
ether was used for the extraction process of themixture. After
that the ether layer was separated and left to evaporate. The
remained residue was dissolved in 25 mL of methanol. This
resulting solution was used as test solution [40].
2.1.3. Chromatographic Conditions for UltraHigh Performance
Liquid Chromatography. The preparation of diosgenin was
done with Chromaster Rs ultra high performance liquid
chromatography system (with a 6430 diode array detector
(DA), 6270 autosampler, 6170 binary pump, 6310 column
oven, software Agilent Open LAB chromatography data
system). Diosgenin was separated on a reverse-phase 10 mm
× 4.6 mm x 2.5 𝜇m Kinetex XB-C18 column. The mobile
phase was prepared from water (solvent A) and acetonitrile
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(solvent B). The mobile phase was degassed and filtered
through 0.45 𝜇m filter before use. The gradient program
used was from A to B (10:90 v/v); 20-21 min, linear change
from A-B (10:90 v/v) to A-B (2:98 v/v); 21-25 min, constant
change from A-B (2:98 v/v); 25-26 min, linear changes from
A-B (2:98 v/v) to A-B (10-90 v/v); and 26-30 min, constant
change from A to B (10-90 v/v). The flow rate of the mobile
phase was 0.7 mL/min. The temperature of the column
was set to 25∘C. The injection volume was 10 𝜇L. The DA
was set at 254 nm to acquire the chromatogram. Diosgenin
was identified by comparing the retention time and spectra
obtained from sample and standard solutions (see Figure 1)
[1]. We performed a total ion chromatogram of fenugreek
(alcoholic extract) in negative ionization mode including
fragmentation spectra of the parent ion (see Figure 2) [40, 41].
2.2. Animals and Protocols
2.2.1. Ethics. The study was approved by and was in accor-
dance with the guidelines of and the Animal Ethics Commit-
tee of the University of Debrecen (25/2013 DE MA´B).
2.2.2. Animals. Male Wistar rats (n=42) were used through-
out the study. Rats were maintained in a controlled environ-
ment (22-24∘C, 12-12 h light/dark cycle). For the animals a
week of acclimation period was provided; thereafter the rats
were randomly selected into six experimental groups: healthy
control (C), high-fat diet control (HF), high-fat diet + 1mg/kg
diosgenin (1D), high-fat diet + 10 mg/kg diosgenin (10D),
high-fat diet + 50 mg/kg diosgenin (50D), and high-fat diet +
0,2 mg/kg fenugreek seed (FG). The healthy control rats had
access to a standard laboratory chow (S8106-S011 SM R/M-
Z+H, ssniff Spezialdia¨ten GmbH, Germany) and fresh tap
water ad libitum. Animals in the five other groups received ad
libitum a diet with high proportion of crude fats and carbohy-
drates, defined as high-fat diet (HFD) and 5% sucrose in the
drinking water. This special rodent chow (“824018-45%AFE
FAT”) was provided by “Special Diets Services”, UK. For the
treated groups, the previously mentioned diosgenin doses, or
the thoroughlymilled fenugreek seedswere incorporated into
the food. As the endpoint of the experiment the seventh week
of treatment period was determined.
2.2.3. Hyperinsulinemic Euglycemic Glucose Clamp (HEGC).
The hyperinsulinemic euglycemic glucose clamp (HEGC)
method is a well-known and the most acceptance investiga-
tion to determine the exact and precise insulin sensitivity of
insulin dependent tissues described by DeFronzo et al. [42,
43]. According to our previously configured and validated
method to measure whole body insulin sensitivity [44]
we performed the HEGC method on each animal of our
current investigation.The animals needed to be anaesthetized
before the procedure. After an overnight starvation, general
anaesthesia was induced and sustained by an intraperitoneal
injection of 50 mg/kg sodium thiopental (Thiopental San-
doz, Sandoz Pharmaceutical PLC, Switzerland). To allow the
spontaneous breathing of the animals, a polyethylene tube
was inserted into the trachea. The HEGC method presumes
two separate venous infusion lines for the administration
of the insulin and glucose solution and an arterial cannula
that serves for blood sampling for the subsequent deter-
mination of blood glucose levels and for monitoring the
blood pressure during the whole period of the investigation.
Two branches of the jugular vein and same side carotid
artery were exposed and cannulated. After thirty-minute
stabilization period continuous insulin (Humulin R, Eli
Lilly, Indianapolis, IN, USA) and 20% w/v glucose infusion
were initiated simultaneously through the jugular vein. The
rate of insulin infusion was set to 3 mU/kg/min while
the glucose infusion rate was adjusted in accordance with
maintaining the euglycemic (5.5 ± 0.5 mmol/l) blood glucose
status. The blood glucose concentration was determined
before the starting of the infusions (insulin and glucose
respectively), during the first 80minutes of the experiment in
5-minute intervals, and at every 10 minutes after the “steady
state” condition developed, using a blood glucose testing
device (Accu-Chek, Roche Diagnostics, Budao¨rs, Hungary).
In addition, the fasting and steady state levels of insulin were
determined from the plasma obtained from blood samples
collected in EDTA tubes (0.5 ml, in 20 𝜇l EDTA, 10 𝜇l
Trasylol; Bayer, Leverkusen, Germany) before the initiation
of insulin infusion and during the steady state period of
the experiment. The blood samples were centrifuged for two
minutes, at 10.000 g and 4∘C (Centrifuge 5415R, Eppendorf
GmbH, Germany), and the plasma was frozen and stored at
-70∘C for further determinations.
2.3. Sample Preparation andDetermination ofHormone Levels
2.3.1. Description of the Blood Sample Preparation. To deter-
mine the plasma concentration of insulin, IGF-1, T3, T4,
and GH from each animal blood samples were collected into
EDTA-coated blood collection tubes (BD, Franklin Lakes,
NJ, USA). The samples were centrifuged at 3000 rpm for 10
min (Centrifuge 5418, nonrefrigerated, with rotor FA-45-18-
11, 230V/50-60Hz, 36 ml, 5418 000.017).The plasma was then
aliquoted and stored frozen at -20∘C until analysis.
2.3.2. Determination of Insulin. The concentration of insulin
was determined using a commercially available ELISA kit
(Insulin ELISA, Immuno Diagnostics, Woodland Hills, Cali-
fornia, USA, kit number: 1606-15). The absorbance was mea-
sured at 450 nm colorimetrically. The insulin concentrations
were determined by comparing the absorbance values of the
samples to the standard curve. The insulin concentrations
were expressed as plasma insulin concentration (in 𝜇IU/mL).
The reagents were prepared according to the manufacturer’s
instructions. 50 𝜇L samples were added to sample wells.
The standard curve was prepared as it was described in the
protocol and 50𝜇L of the diluted standard solutionwas added
to the appropriate wells. 100 𝜇L of the Enzyme Reagent was
added to each well; then themicroplate was swirled gently for
20-30 seconds tomix and coveredwith a plastic wrap andwas
incubated for 120 minutes at room temperature (20-27∘C).
The liquid of themicroplatewas discarded by decantation and
tap and blot the plate dry with absorbent paper. 350 𝜇L of
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Figure 1: Chromatogram of fenugreek (Trigonella foenum-graecum L.).
wash buffer was added, decanted, and aspirated, and this step
was repeated two additional times for a total of three washes.
100 𝜇L of working substrate was added to solution in all wells
and the microplate was incubated at room temperature for 15
minutes. Then 50 𝜇L of stop solution was added to each well
and mixed gently 15-25 seconds. Absorbance was measured
at 450 nm. Sample insulin concentration was compared with
the insulin standard curve and the concentration of insulin
was expressed as plasma insulin concentration (in 𝜇IU/ml).
2.3.3. Determination of Insulin-Like Growth Factor-1 (IGF-
1). The insulin-like growth factor-1 was determined using
a commercially available ELISA kit (Eagle Biosciences,
INC., Nashua, New Hampshire, kit number: IGF31-K01).
The reagents were prepared according to the manufac-
turer’s instructions. Standards and samples were prepared as
described in the protocol book. 20 𝜇L of the samples and
standard were added to the appropriate wells and 100 𝜇L of
the biotinylated IGF was added to each well and the plate was
incubated at room temperature for two hours. The solution
was aspirated from the microplate and each well was rinsed
with 300𝜇L of 1x Wash solution and repeated 3 times. 150
𝜇L of the enzyme complex was added to each well after the
wash process and the plate was incubated one hour at room
temperature.Then thewash process was repeated three times.
100 𝜇L of substrate was added to each well and incubated for
15 minutes. 100 𝜇L of stopping solution was added to each
well. Absorbance was measured at 450 nm. Sample IGF-1
concentration was compared with the IGF-1 standard curve
and the concentration of IGF-1 was expressed as plasma IGF-
1 concentration (in ng/mL).
2.3.4. Determination of Growth Hormone (GH). The concen-
tration of growth hormone was assessed with a commercially
available assay kit (Elisa Cloud Immunoassay, Huston, USA,
kit number: SEA044). In the first step, the wells were
determined wells for diluted standards, blank, and samples.
100 𝜇L of each of dilutions standards, blank, and samples was
added to the correct wells, then the plate was covered and
incubated for 1 hour at 37∘C. After incubation the liquid was
removed from each well and 100 𝜇L of Detection Reagent
A working solution was added to each well and incubated
for 1 hour at 37∘C. The plate was washed with 350 𝜇L of 1x
wash solution and repeated 3 times. After the last wash any
remaining wash buffer was removed by aspirating and 100 𝜇L
of Detection Reagent B working solution was added to each
well and incubated for 30 minutes at 37∘C. The aspiration
and wash process were repeated 5 times. After the washing
process 90 𝜇L of Substrate Solution was added to each well;
then the plate was covered and incubated for 10-20 minutes
at 37∘C. After incubation, 50 𝜇L of Stop Solution were added
to each well. Absorbance was measured at 450 nm. Sample
GHconcentrationwas comparedwith theGH standard curve
and the concentration of GH was expressed as plasma GH
concentration (in pg/mL).
2.3.5. Determination of Triiodothyronine (T3). The concen-
tration triiodothyronine was determined using a commer-
cially available ELISA kit (Wuxi Donglin Sci & Tech Devel-
opment Co., Ltd. Wuxi, Jiangsu, China, kit number: DL-T3-
Ge). The color change was measured spectrophotometrically
at a wavelength of 450 nm. The concentrations of T3 in the
samples were determined by comparing the absorbance of
the samples to the standard curve. The T3 concentrations
of the samples were expressed as plasma T3 concentration
(in ng/mL). The reagents were prepared according to the
manufacturer’s instructions. A standard curve was prepared;
the diluted standard solutions, the blank, and the samples
were added to the appropriate wells (50 𝜇l). 50 𝜇L of
Detection A was also added to each well immediately and the
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Figure 2: Total ion chromatogram of alcoholic extract of fenugreek (Trigonella Foenum-graecumL.) in negative ionizationmode (a) including
fragmentation spectra of the parent ion (b).
plate was shaking gently and covered with a plate sealer and
incubated for 1 hour at 37∘C.The solution was aspirated from
the microplate and each well was washed with 350𝜇L of 1x
Wash solution 3 times. To each well then 100 𝜇L of Detection
Reagent B was added; then the plate was incubated at 37∘C
for 1 hour. After the incubation, the aspiration/wash cycle was
repeated 5 times; then 90 𝜇L of Substrate Solution was added
to each well after the end of the wash process. The plate was
incubated for 15-25∘C minutes at 37∘C; then 50 𝜇L of Stop
solution was added to each well. Absorbance was measured
at 450 nm. Sample T3 concentration was compared with the
T3 standard curve and the concentration of T3 was expressed
as plasma T3 concentration (in ng/mL).
2.3.6. Determination of Thyroxine (T4). The concentrations
of thyroxine were determined using a commercially available
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ELISA kit (Wuxi Donglin Sci & Tech Development Co.,
Ltd. Wuxi, Jiangsu, China, kit number: DL-T4-Ge). The
reagents were prepared according to the manufacturer’s
instructions. A standard curve was prepared; the diluted
standard solutions, the blank, and the samples were added
to the appropriate wells (50 𝜇l). 50 𝜇L of Detection A
was also added to each well immediately and the plate
was shaking gently and covered with a plate sealer and
incubated at 37∘C for 1 hour.The solution was aspirated from
microplate. Each well was washed with 350𝜇L of 1x Wash
solution 3 times. To each well then 100 𝜇L of Detection
Reagent B was added and at 37∘C the plate was incubated
for 1 hour. After the incubation, the aspiration/wash cycle
was repeated 5 times; then 90 𝜇L of Substrate Solution was
added to each well after the end of the wash process. The
plate was incubated for 15-25∘C minutes at 37∘C; then 50
𝜇L of Stop solution was added to each well. Absorbance
was measured at 450 nm. Sample T4 concentration was
compared with the T4 standard curve and the concentra-
tion of T4 was expressed as plasma T4 concentration (in
ng/mL).
2.4. Formulas for Calculations [45–49]: Glucose infusion rate
(GIR) is
𝐺𝐼𝑅 =
glucose infusion (mg/min)
body weight (kg)
(1)
Metabolic clearance rate of insulin (MCRI), expressed in
mU/m2/min, is
𝑀𝐶𝑅𝐼 =
insulin infusion rate
steady state plasma insulin concentration – basal plasma insulin concentration (2)
Insulin sensitivity index (ISI), expressed in
mg/kg/min/mU/mL, is
𝐼𝑆𝐼 =
glucose infusion rate
steady state plasma insulin concentration (3)
Quantitative insulin sensitivity check index (QUICKI) is
𝑄𝑈𝐼𝐶𝐾 =
1
log (fasting plasma insulin (𝜇IU/mL)) + log (fasting plasma glucose (mg/dL)) (4)
To estimate insulin resistance the universally accepted home-
ostatic model assessment (HOMA) was applied.
HOMA for insulin resistance (HOMA-IR) is
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
fasting plasma insulin (𝜇IU/mL) × fasting plasma glucose (mmol/L)
22.5
(5)
2.5. Data Analysis. Statistical analysis was carried out with
GraphPad Prism 7.04. All data were analyzed with one-way
analysis of variance (ANOVA) followed by Tukey posttesting.
In the figures, data are presented as mean ± SEM. ∗, ∗∗,
and ∗ ∗ ∗ indicate significant difference in comparison to
the healthy control group (∗ for p<0.05, ∗∗ for p<0.01, and
∗ ∗ ∗ for p<0.001). #, ##, and ### indicate the statistically
significant difference compared to the HFHSD (high-fat and
high-sugar diet) control group (p<0.05, p<0.01, and p<0.001,
respectively). §, §§, and §§§ indicate significant difference
compared to the corresponding 0 min value (p<0.05, p<0.01,
and p<0.001, respectively).
3. Results
Fasting glucose levels showed statistically significant differ-
ence only between the 1D and HF group (see Figure 3). In the
steady state, since in HEGC blood glucose is artificially kept
in the euglycemic state, there was no significant difference
between groups.
Fasting plasma insulin levels were not statistically sig-
nificant between the groups (see Figure 4). In the steady
state period of HEGC due to the insulin infusion, insulin
levels elevated significantly in each group compared to their
respective fasting values. Furthermore, 1D animals showed a
significant decrease to healthy controls and high-fat controls,
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Figure 3: Blood glucose levels after 10 weeks of diosgenin or
fenugreek treatment.
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Figure 4: Plasma insulin levels after 10 weeks of diosgenin or
fenugreek treatment.
while the FG group had a statistically significant decrease
in insulin levels compared to the HF group only. 10D rats,
however, showed a significant increase in insulin levels
compared to both C and HF animals.
There was no statistically significant difference between
the groups in glucose infusion rate (see Figure 5).
In the 10D animals, insulin sensitivity index significantly
decreased compared to healthy controls (see Figure 6).
The FG group showed a statistically significant elevation
compared to the HF rats.
The metabolic clearance rate of insulin was significantly
increased in 1D and fenugreek groups compared to both the
healthy and high-fat controls (see Figure 7). 10D rats showed
a statistically significant decrease in comparison to the C and
HF groups.
In HOMA-IR, the groups showed no statistically signifi-
cant difference between each other (see Figure 8).
QUICKI showed no statistically significant difference
between the groups (see Figure 9).
In 0 min, IGF-1 levels showed no statistically significant
difference between the groups (see Figure 10). In the steady
state period of HEGC, however, IGF-1 levels significantly
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Figure 5: GIR after 10 weeks of diosgenin or fenugreek treatment.
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Figure 6: ISI after 10 weeks of diosgenin or fenugreek treatment.
increased in HF, 1D, 10D, and FG animals compared to their
respective 0 min values.
In the fasting state, all diosgenin groups, but not the FG
group, showed a significant increase compared to the HF
animals (see Figure 11). In the steady state period of the
HEGC, however, GH levels increased in the healthy controls
and the HF group, although without reaching significance
compared to the corresponding 0 min value, and the dios-
genin groups showed an apparent dose-dependent decrease
in GH levels. With the 10D and 50D rats the decrease was
statistically significant compared to healthy controls, and the
50D group also showed a significant decrease to its 0 min
value. Fenugreek treatment caused a significant decrease in
GH levels by the steady state period compared to both the C
and HF groups.
Fasting levels of T3 were significantly decreased in all
groups compared to healthy control rats (see Figure 12). Dur-
ing steady state, however, T3 decreased in healthy controls,
despite not reaching statistical significance. The rats treated
with diosgenin showed significant increase compared to their
corresponding 0min values, and the 50Dgroup also showed a
significant elevation in T3 levels compared to the steady state
value of HF animals.
The FG group showed a statistically significant increase
in fasting T4 levels compared to healthy and high-fat controls
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treatment.
(see Figure 13). In the steady state period of HEGC there was
an apparent increase in T4 levels in the diosgenin treated ani-
mals, but only the 10D group reached statistical significance.
The fenugreek seed treated rats, however, showed a significant
decrease in T4 levels compared to their elevated fasting value.
4. Discussion
Literature data confirms that fenugreek is a widely used plant
since ancient times as a spice, herb, nutritional supplement, or
a therapeutic agent in different types of disorders, including
diabetes mellitus, metabolic syndrome or hyperlipidaemia
[3, 50–53]. It is also very effective in reducing oxidative stress
damage and stimulating apoptosis in hyperplasia of different
types of cells [54–58]. Both the leaves and the seeds can
be administered in therapeutic or nutritional regards [53].
Some researchers and pharmaceutical manufacturers use the
aqueous or alcoholic extracts of the fenugreek to enhance
its effect or to prepare the best formulation of the plant.
We reported in our previous study that the aqueous and
alcoholic fenugreek extracts are significantly different in the
profile of bioactive compounds [1]. According to our results,
4-HIL, asparagine, and various nucleotides were present only
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Figure 9: QUICKI after 10 weeks of diosgenin or fenugreek
treatment.
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Figure 10: IGF-1 levels after 10 weeks of diosgenin or fenugreek
treatment.
in the aqueous extract, and on the other hand the flavonoids,
soyasaponins, steroidal saponins, and some vitamins such
as vitamin C and B3 were detectable only in the alcoholic
extract. Since the different types of extracts contain only a
part of the active compounds of fenugreek; therefore, the
whole plant is preferable to be administered to the healthy
or diseased.
Several research data supports that besides insulin regu-
lation fenugreek can also influence the synthesis and function
of other metabolic hormones, like IGF-1, GH, T3, and T4
[59–62]. All these hormones play an important role in the
regulation of glucosemetabolismand the pathomechanismof
diabetes mellitus. IGF-1 is by structure and function familiar
to insulin, and in case of insulin deficiency it can activate
the insulin receptor but the hypoglycemic effect develops at
a slower rate [63]. Furthermore, IGF-1 is a very important
antiapoptotic and hypertrophic agent, involved especially in
the thyroid tissue hyperplasia [64–67]. Moreover, IGF-1 also
stimulates the production and secretion of TSH. Both effects
can contribute to the increase of thyroid hormone levels. The
growth hormone is considered the most important anabolic
hormone, with major role in lipolysis and the synthesis
of proteins. GH plays an important role in the regulation
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Figure 12: T3 levels after 10 weeks of diosgenin or fenugreek
treatment.
of glucose metabolism, contributing to the development
of hyperglycemia, hyperinsulinemia, and insulin resistance
[68–75]. In addition, GH secretion can be modified by
thyroidal hormones: in hypothyroidism GH levels and GH
response is decreased [76]. Thyroidal hormones are able
to influence metabolism in the whole body. They have an
important role in metabolic regulation and growth, but in
addition these endocrine compounds can modify cardio-
vascular functions, energy balance, and the central nervous
system function. Thyroidal hormones greatly influence glu-
cose metabolism either via altering IGF-1 and GH functions
and increasing hepatic glucose production. Apart from being
used in hypothyroidism they have indication in the treatment
of depression, as well as in treatment of obesity due to the
stimulation of lipolysis, but long-term usage is limited by
their possible diabetes promoting and cardiovascular side
effects.
During hyperinsulinemic euglycemic glucose clamp per-
formed at the end of the six week long experimental period
we found no significant differences between the groups
regarding glucose infusion rate, suggesting that in response
to the insulin infusion and consequent hyperinsulinemia
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Figure 13: T4 levels after 10 weeks of diosgenin or fenugreek
treatment.
the rate of disappearance of glucose have not changed;
therefore the insulin stimulated glucose uptake was the same.
However, the parameters calculated from blood samples
taken in fasted and steady state suggest that the lowest dose of
diosgenin and the comparable dose fenugreek seed treatment
significantly improved insulin resistance. In the fenugreek
group insulin sensitivity index was increased, showing that
less amount of insulin was needed to achieve the same rate of
disappearance of glucose from blood circulation compared
to other groups. This finding is also corroborated by the
increased metabolic clearance rate of insulin, suggesting
that the body had to compensate against hypoglycemia by
eliminating excess insulin, an effect also shown by rats treated
with 1 mg/kg diosgenin. Though the latter group failed to
show an increased ISI, the elevated MCRI demonstrates
the improved insulin sensitivity and glucose uptake. The
explanation behind the difference in insulin sensitivity effect
between the fenugreek seed and the comparable dose of
diosgenin might be that fenugreek might be that apart from
diosgenin; fenugreek seeds contain other active compounds
that can influence glucose metabolism. One such compound
is the newly identified 4-hydroxyisoleucine (4-HIL). Several
studies demonstrated that 4-HIL is able to enhance insulin
sensitivity via different molecular targets, such as AMP-
activated protein kinase, suppressor of cytokine signalling-
3, insulin receptor substrate-1, and in some reports showing
an effect comparable to that of metformin [77–79]. The 50
mg/kg diosgenin treatment failed to alter insulin sensitivity,
but rats treated with 10 mg/kg diosgenin showed a marked
drop in ISI and MCRI, suggesting insulin resistance in
peripheral tissues. This seemingly contradictory response
compared to the lowest dose of diosgenin might be explained
with the phenomena of hormesis, a relatively new, but not
well understood theory in toxicology that states that certain
compounds in low dose have a stimulating, but in high doses,
an opposite, inhibitory effect. Hormesis might be explained
if we assume that in low doses the toxic compound activates
adaptive responses in the body, thus achieving a beneficial
effect, but in higher doses these adaptive mechanisms cannot
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counterbalance the stress and undesired effects manifest [80–
82]. Based on our results we suggest that, in 1 mg/kg dose,
diosgenin has an insulin sensitizing effect, but in 10 mg/kg
dose it promotes insulin resistance.
Continuous insulin infusion effectively increased IGF-1
levels in the high-fat control, 1 and 10 mg/kg diosgenin, as
well as in the fenugreek groups. IGF-1 elevation might have
appeared as a result of hyperinsulinemia and the significantly
increased GH levels. In response to elevated basal GH
levels IGF-1 increased by the steady state period, activating
growth hormone inhibiting hormone (GHIH), and, in turn,
decreasing GH levels that can contribute to normalization of
blood glucose levels [83]. Hyperinsulinemia also stimulates
thyroid hormone production and secretion, and IGF-1 levels
elevate in the thyroid gland, possibly as a result of elevated
GH [84]. IGF-1 stimulates TSH and the proliferation of
thyroid tissue that leads to increased secretion of thyroid
hormones and consequent hypoglycemia. In the state of high
plasma glucose levels less T4 prohormone is transformed into
T3, T3/T4 ratio decreases, and obesity might develop [60].
Our results showed that in chronic diosgenin and fenugreek
treatment the basal level of thyroid hormones, especially T3
significantly decreased, but the consequent IGF-1 elevation in
response to hyperinsulinemia in the steady state effectively
balances this reduction in the diosgenin groups. The FG rats
showed a significant elevation of basal T4 levels, but in the
steady state period the insulin infusion reduces T4, possibly
through stimulating its transformation into T3 due to ele-
vated GH that promotes hypothyroidism [85, 86]. Our results
corroborate that there are complex feedbackmechanisms and
interplay between the studied anabolic hormones that play
an important role in the regulation of glucose metabolism,
development of insulin resistance, and modulating insulin
sensitivity. Our additional find is that fenugreek seed may
have different physiological effects than its active component
diosgenin due to the fact that apart from compounds with
potentially therapeutic value it might also contain molecules
that cause undesired or even toxic side effects, especially in
long-term treatment. However, it is important to note the
significance of proper dosing, since low dose had beneficial
effects, but elevation of doses impaired insulin sensitivity and
the homeostasis of the examined hormones.
5. Conclusion
Our study shed light to that chronic consumption of fenu-
greek seed is able to influence the complex interplay of
anabolic hormones. Our results also indicate that apart from
its proven insulin sensitizing effect fenugreek might have a
therapeutic potential in the adjuvant treatment of thyroid
diseases. We plan to conclude further research to determine
the effect of fenugreek and its saponin agents in different
thyroid disease models.
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